PeptMentor
CalculatorsHow we source
PeptMentor
PeptMentor
Peptides
Eloralintide
Retatrutide
GHK-Cu
Pinealon
KPV
KLOW
All peptides
Compared
Eloralintide vs cagrilintide
Eloralintide vs retatrutide
Retatrutide vs tirzepatide
Guides and tools
Bac water for peptides
How to reconstitute peptides
Peptide reconstitution calculator
All guides
About
How we source
About
Editorial policy
Open the peptide calculator
PeptMentor

Plain answers about peptides and GLP-1 medicines. Every figure links to its source and says what kind of study it came from.

No dose advice. No sponsors, sellers or affiliate codes.

Peptides

  • Eloralintide
  • GHK-Cu
  • KLOW
  • KPV
  • Pinealon
  • Retatrutide
  • All peptides

Compare

  • Eloralintide vs cagrilintide
  • Eloralintide vs retatrutide
  • Retatrutide vs tirzepatide

Guides and tools

  • Peptide reconstitution calculator
  • Bac water for peptides
  • How to reconstitute peptides
  • All guides

About us

  • About
  • How we check facts
  • Editorial policy
  • Sources
  • Contact
© 2026 PeptMentor LLC. For information only, not medical advice. In an emergency call 911.
Medical disclaimerTermsPrivacyConsumer health data
  1. /Home
  2. /Peptides
  3. /Retatrutide

Weekly shot · weight loss · in late trials

Retatrutide: trial doses, side effects and results

A weekly shot that helped people in trials lose about a quarter of their weight. Whether you are curious, starting, or already on it, here is what helps.

A woman walking her bicycle along a quiet tree-lined path
StatusIn trials, not approved
How sure is science?Large trials in people
Biggest trial result−25% vs −4% placebo, 80 weeks
Most common side effectNausea, about 4 in 10

Status as of November 17, 2026. For information only, not medical advice: read the medical disclaimer.

Where are you with Retatrutide?

Before you decide

Good place to start. Here is what we would want to know before deciding, in plain words.

It is not approved yet

Retatrutide is still in trials. The only legal ways to get it are joining a trial, or a special access programme your doctor applies for. Lilly plans to ask the FDA for approval in early 2027.

Status and timeline →

What it did in trials

In the biggest trial, people on the top dose lost about a quarter of their weight over 80 weeks. People on placebo lost about 4%.

Human randomised trialTrial results →

What it felt like

Stomach upset was the most common side effect: about 4 in 10 felt sick at some point (1 in 7 on placebo). About 1 in 9 stopped because of side effects.

All side effects →

Bought online is not the trial drug

The FDA has warned sellers of “research use only” retatrutide. What is in those vials cannot be checked, so trial results do not describe them.

What the FDA says →

Take these questions to your doctor

  • Is there a trial I could join, or could I qualify for expanded access?
  • What dose would I start on, and how would it go up?
  • I take tirzepatide or semaglutide now. What would a switch look like, given no trial has tested one?
  • Could any of my medicines interact with it, like insulin or a sulfonylurea?
  • Will it change how well my birth control pills work? The label of a related drug, Zepbound, warns about this.
  • What should I do if side effects do not ease?
  • How long would I stay on it, and what happens when I stop?

Coming Pick your questions and print them as one page.

Your first weeks

The first weeks are where most people struggle. Here is what the trials saw and what the label of a similar approved drug advises.

Trials started low and went slowly

Everyone in the big trials began on a low dose that went up every 4 weeks. Starting lower partly cut stomach side effects. This describes the trials, not a plan for you: dose decisions belong with your prescriber.

How trials stepped up →

Mixing a vial? Do the maths first

The calculator turns the numbers on a label into units on a U-100 syringe. It never suggests a dose.

Open the calculator →

Small habits from the label

The label of a related approved drug covers injection spots, sharing needles, food and your medicines list.

The label tips →

Write down your starting point

Weight, waist and a photo on day one make it much easier to see change later.

Coming A progress log that stays only on your device.

What to track →

Living with it

You’re on it. Here’s how to feel better day to day, and how to tell if it’s working.

If your stomach is upset

Drink fluids, and tell your provider if it is severe or will not go away.

What the label says →

Tingling or burning skin?

Odd skin feelings were reported more often on retatrutide than placebo in every large trial, in up to about 1 in 5 people on the top dose. Nobody has explained why yet. Mention it to your doctor.

The trial numbers →

Is it working?

In trials, weight was still falling between weeks 24 and 48, so early weeks rarely tell the whole story. Look at your weekly average, not one day.

What to track →

Thinking of switching from tirzepatide?

No trial has tested a switch to retatrutide, so nobody can say from evidence how to do it. Plan any switch with your prescriber.

What is known →

Got it online? Lower the risk.

No judgement. We won’t tell you where to buy or how much to take, but these steps lower the risk whatever you use:

  • A label saying “research use only” or “not for human consumption” means it was not made or checked for people. The FDA has sent warning letters over exactly these labels.
  • Tell your doctor what you are taking, even if it feels awkward. It changes what they watch for.
  • Learn the warning signs in “Something feels off” before you need them.
  • Report a bad reaction to the FDA’s MedWatch. It helps everyone.
Source: FDA MedWatch[1]

When to get help

Most side effects are mild and fade. A few need a call today, and a few need help right now. Here is how to tell them apart.

Emergency: call 911 (or your local emergency number). Possible overdose or wrong amount: Poison Help, 1-800-222-1222, free and open 24 hours. Report a bad reaction to the FDA through MedWatch.

Get emergency help now if you have

  • Swelling of your face, lips, tongue or throat, trouble breathing or swallowing, or fainting.
  • Severe pain in your stomach area that will not go away, with or without vomiting. It can spread to your back.
Source: serious side effects in the Zepbound Medication Guide, a related approved drug[2]

Call your doctor today if you have

  • Pain in your upper right stomach, fever, yellow skin or eyes, or clay-coloured stools (gallbladder).
  • Vomiting or diarrhoea and you can’t keep fluids down.
  • Shakiness, sweating, confusion or a fast heartbeat, especially if you take insulin or a sulfonylurea (low blood sugar).
Source: Zepbound Medication Guide[2]Every warning sign on the label →

Usually not urgent, but worth mentioning

  • Mild sickness, fewer bowel movements or a smaller appetite in the first weeks.
  • Tingling or sensitive skin.
  • A faster resting heart rate. In trials it rose with dose, peaked around week 24, then came down.

The science, if you want it

Every number below says what kind of study it came from. Bracketed numbers point to the sources listed at the end.

Human RCT (phase 3)Not approved anywhere
CellAnimalSmall humanHuman randomised trialApproved

Best evidence: human randomised trial

Facts checked 2026-11-17 · by PeptMentor Team · How we source

On this page
What the trials saw, week by weekLiving with it day to dayWhen to call a doctorIs it working? How to track itWhy results varySwitching from tirzepatide to retatrutideWhat is retatrutide?How retatrutide worksIs retatrutide approved? Status and timelineWhat the retatrutide trials foundRetatrutide dosing studied in trialsRetatrutide calculator: vial and syringe arithmeticRetatrutide side effects reported in trialsMuscle and body compositionProducts sold online as retatrutideOngoing retatrutide trialsRetatrutide compared with other drugsSources

What the trials saw, week by week

Weight change in retatrutide trials, by week
  1. Weeks 1 to 16Lilly press releases, 2026-05-21 and 2025-12-11
    A slow climb to the full dose

    In the large trials, everyone started on a low dose. The dose went up every 4 weeks. The top dose began in week 17. This was the trial plan, not a plan for you.

    Company press releaseLilly press releases, 2026-05-21 and 2025-12-11
  2. Week 12PMID 36354040
    An early look in a small study

    In a small study of 72 people with type 2 diabetes, the group that stepped up to the top dose lost about 9 kg more than placebo (8.96 kg).

    Small human study[3]
  3. Week 24PMID 37366315
    About one sixth of body weight

    In the phase 2 trial, the top-dose group had lost 17.5% of their weight on average.

    Human randomised trial[4]
  4. Week 48PMID 37366315
    Still going down

    By week 48, the same group had lost 24.2%, so weight was still falling between weeks 24 and 48.

    Human randomised trial[4]
  5. Week 80PMID 42814954
    About a quarter of body weight

    In TRIUMPH-1, people on the top dose lost 25.0% on average. People on placebo lost 3.9%.

    Human randomised trial[5]
  6. Week 104Lilly press release, 2026-05-21
    A longer look in some people

    In a group with a BMI of 35 or more who kept going to two years, the top-dose group reached 30.3% (efficacy estimand).

    Company press releaseLilly press release, 2026-05-21

Averages from trials, not a forecast for you. Each step comes from a different trial or time point, so the steps are not one curve. Sources: step-up plan, Lilly releases for TRIUMPH-1 (2026-05-21) and TRIUMPH-4 (2025-12-11); week 12[3]; weeks 24 and 48[4]; week 80[5]; week 104, Lilly release 2026-05-21.

The papers and releases we read do not say in which weeks stomach side effects started or eased. They also do not report day-by-day effects, so we leave those out.

Living with it day to day

Retatrutide has no label yet
Approved drugs come with a label that covers storage, travel and missed doses. Retatrutide has none, so there are no official rules for it. The trials gave it as a shot under the skin once a week.
From the label of a related approved medicine
  1. Change where you inject

    Use a new spot with each weekly shot. You can use the same area of your body, but not the same spot.

  2. With or without food

    It can be taken with or without food.

  3. Never share pens or needles

    Not even with a new needle. You could pass on or catch a serious infection.

  4. Drink fluids

    Diarrhoea, nausea and vomiting can make you lose fluids. Drinking fluids helps lower the chance of dehydration, which can harm your kidneys.

  5. Speak up if it won't go away

    Tell your provider about stomach problems that are severe or will not go away.

  6. Know the signs of low blood sugar

    The risk may be higher if you also take insulin or a sulfonylurea. Signs include shakiness, sweating, dizziness, headache, confusion and hunger.

  7. Keep a list of your medicines

    Show it to your provider and pharmacist when you get a new one.

  8. Tell every provider before surgery

    Food can get into the lungs during procedures that put you to sleep. Tell all your providers before any surgery.

Every tip comes from the Zepbound (tirzepatide) Medication Guide[2], revised 08/2026. Tirzepatide is a related approved medicine that acts on two of the same receptors. Retatrutide has no label of its own, no study has tested these tips with retatrutide, and nothing here is advice to change a dose.

We have not added advice on what to eat when your appetite drops. We will only add it from published guidance, with the source named.

When to call a doctor

These warning signs come from the Zepbound (tirzepatide) Medication Guide[2], revised 08/2026, a related approved medicine. Retatrutide has no label of its own, so these are not retatrutide warnings.

Call your doctor or prescriber today if
  • Stomach problems that are severe or will not go away.
  • Nausea, vomiting or diarrhoea that does not go away.
  • Pain in your upper belly, fever, yellow skin or eyes, or clay-colored stools. These can be signs of gallbladder problems.
  • Severe belly pain that will not go away, with or without vomiting. You may feel it from your belly to your back. This can be a sign of an inflamed pancreas.
  • A lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
  • Changes in your vision, if you have type 2 diabetes.
Get emergency help now if
  • Swelling of your face, lips, tongue or throat.
  • Problems breathing or swallowing.
  • A severe rash or itching, fainting or feeling dizzy, or a very fast heartbeat.
  • You took too much. Call Poison Help at 1-800-222-1222 or go to the nearest emergency room.

Is it working? How to track it

Simple things to track
  • Weigh yourself at the same time of day. Look at the weekly average, not one day.
  • Measure your waist once a week, at the same spot.
  • Take photos in the same light and the same clothes.
  • Notice how your clothes fit.
  • Note any side effects: what, when, how bad and how long.

These are ways to keep a record. They are not targets, and they do not replace checks by your prescriber.

Why results vary

Trials cannot explain one person's result, and this section does not offer troubleshooting. It reports what the trials show about how much results varied, how long the doses took to reach the top step, and what is unknown.

Arm≥5% lost≥10% lost≥15% lost
4 mg92%75%60%
8 mg100%91%75%
12 mg100%93%83%
Placebo27%9%2%

Phase 2 obesity trial, share of people who reached each amount of weight loss at 48 weeks. Source: NEJM 2023[4].

Results varied between people. Even on 12 mg in phase 2, 17% did not reach 15% weight loss (table above). In TRIUMPH-1, 15.3%, 37.9% and 45.3% (4 / 9 / 12 mg) lost 30% or more, vs 0.5% on placebo (efficacy estimand, Lilly press release 2026-05-21).

Source limit

Whether the full TRIUMPH-1 paper reports weight plateaus over time; we have read only its abstract.

Switching from tirzepatide to retatrutide

No published or registered trial has tested switching from tirzepatide (Mounjaro, Zepbound) or semaglutide to retatrutide. Phase 3 trials excluded people who had taken a weight-loss drug in the 90 days before screening[6][7]. So there is no trial evidence on how to switch, what dose to start at after tirzepatide, or what to expect.

  • Is there a reta mg to tirz mg conversion? No. Lilly has not published one, and no trial produced one. A milligram of one molecule does not equal a milligram of another, so the numbers cannot be lined up. Conversion tables found online have no trial source.
  • Who decides a switch: for approved drugs, switching is a prescriber's decision. Retatrutide is not approved, so there is no prescribing information to follow.
  • Tirzepatide and retatrutide together: no trial has given both drugs together.
  • What will be known next: TRIUMPH-5 compares retatrutide with tirzepatide in about 800 people with obesity[7]. It tests the two drugs side by side, not a switch. No results had been reported by 2026-11-17.

What is retatrutide?

One molecule, three hormone receptors, a half-life of about 6 days, other names.

Retatrutide is a single peptide molecule made by Eli Lilly that activates the GIP, GLP-1 and glucagon receptors[8]. In trials it is injected under the skin once a week.

Other names. Lilly's code name is LY3437943[8]. "Reta" is the community short name, and "retratrutide" is a common misspelling. PubChem lists the sodium salt with the formula C221H342N46O68 (PubChem CID 171934787).

Why once a week. In a phase 1b study of 72 people with type 2 diabetes, retatrutide had a half-life of about 6 days, and blood levels rose in proportion to the dose, which the authors say supports weekly dosing[3].

How retatrutide works

GIP, GLP-1 and glucagon receptors, and which findings come from mice.

Retatrutide is one molecule that binds three receptors. GIP and GLP-1 are gut hormones that act on appetite and insulin release. Glucagon is a hormone from the pancreas. Some of what is said about the glucagon part online comes from mice, so the table shows where each finding was made.

FindingWhere it was shownSource
Activates GIP, GLP-1 and glucagon receptorsCells[8]
More activity at the GIP receptor; balanced activity at the glucagon and GLP-1 receptorsCells[8]
Glucagon receptor adds extra energy use on top of eating lessObese mice only[8]
Body weight falls with dosePeople: phase 2 and phase 3 RCTs[4][5]

Does retatrutide burn fat? The extra energy use from the glucagon receptor was shown in obese mice[8]. No human study we found shows that retatrutide burns fat directly. What has been measured in people is body composition, covered in muscle and body composition.

Tirzepatide acts on two of the same receptors (GIP and GLP-1). Retatrutide adds the glucagon receptor. For trial results side by side, see retatrutide vs tirzepatide.

Is retatrutide approved? Status and timeline

Not approved. Lilly plans to file with the FDA in Q1 2027. Full timeline.

No. As of 2026-11-17 retatrutide has not been approved by the FDA or any other regulator (Lilly press release on TRANSCEND-T2D-2, 2026-10-28). Lilly says it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027 (Lilly releases, 2026-07-23 and 2026-09-29). Lilly releases up to 2026-11-14 do not announce that the application has been sent.

  1. 2022-08

    Lilly scientists publish the molecule and how it acts on three receptors.

    Coskun et al., Cell Metab[8] Cell
  2. 2022-10

    Phase 1b study in type 2 diabetes (72 people) reports a half-life of about 6 days.

    Urva et al., Lancet[3] Small human study
  3. 2023-06

    Phase 2 obesity trial (338 people) published: up to −24.2% at 48 weeks.

    Jastreboff et al., NEJM[4] Human randomised trial
  4. 2025-12-11

    First phase 3 readout: TRIUMPH-4 (obesity with knee osteoarthritis).

    Lilly press release[9] Company press release
  5. 2026-05-21

    TRIUMPH-1 topline results announced.

    Lilly press release[6] Company press release
  6. 2026-06-05

    Single-patient expanded access programme first posted.

    ClinicalTrials.gov[10] Trial registry
  7. 2026-06-06

    TRANSCEND-T2D-1 (type 2 diabetes) published.

    Bajaj et al., Lancet[11] Human randomised trial
  8. 2026-07-23

    TRIUMPH-2 and TRIUMPH-3 toplines; Lilly says it plans to submit a BLA in Q1 2027.

    Lilly press release[12] Company press release
  9. 2026-09-29

    TRIUMPH-1 published in NEJM; TRIUMPH-2 published in the Lancet the same day.

    Jastreboff et al., NEJM[5] Human randomised trial
  10. 2026-10-01

    FDA page states retatrutide cannot be used in compounding under federal law.

    FDA: concerns with unapproved GLP-1 drugs[13] Regulator
  11. 2026-10-28

    TRANSCEND-T2D-2, the first head-to-head trial (vs Ozempic 2 mg), topline announced.

    Lilly press release[14] Company press release
  12. 2026-11-08

    TRIUMPH-4 and the TRIUMPH-1 knee osteoarthritis results published in NEJM.

    Schnitzer et al., NEJM[15] Human randomised trial

Expanded access. Lilly lists a single-patient expanded access programme for adults with a BMI of 35 or more, at least two serious obesity complications, no response to the best approved treatment, and no way to join a trial. The treating doctor makes the request[10]. Outside this programme, the only legal way to receive retatrutide is in a trial.

Is there a retatrutide pen or price? No. There is no approved retatrutide product, so there is no approved pen, label or price. Trials give the drug as a weekly injection under the skin.

Compounding. The FDA says: "Retatrutide and cagrilintide cannot be used in compounding under federal law." It also says they are not components of FDA-approved drugs and have not been found safe and effective for any condition[13].

What the retatrutide trials found

Weight results from every published trial, with the estimand named.

Lilly reports two weight numbers for each trial arm. The efficacy estimand assumes everyone stayed on the drug; it is the larger number and the one in headlines. The treatment-regimen estimand counts everyone who was randomised, including people who stopped; the NEJM and Lancet papers lead with it. Each figure below says which one it is.

TRIUMPH-1: mean weight loss at 80 weeks (%) Treatment-regimen estimand Efficacy estimand

Scale: 0–28.3%

4 mg17.6% vs 19%
9 mg23.7% vs 25.9%
12 mg25% vs 28.3%
Placebo3.9% vs 2.2%

Adults with obesity and no diabetes, n=2,339. Treatment-regimen figures: NEJM 2026[5]. Efficacy figures: Lilly press release, 2026-05-21. Bars show weight lost, so larger is more weight lost.

TrialWho took partnWeeksWeight change by armSource
Phase 1bType 2 diabetes7212Up to −8.96 kg vs placebo (3→6→9→12 mg)[3]
Phase 2Obesity338481 mg −8.7%, 4 mg −17.1%, 8 mg −22.8%, 12 mg −24.2% vs placebo −2.1%[4]
Phase 2Type 2 diabetes28136−3.19% (0.5 mg) to −16.94% (12 mg) vs placebo −3.00%[16]
TRIUMPH-1Obesity, no diabetes2,33980TR: −17.6 / −23.7 / −25.0% vs −3.9%. Eff: −19.0 / −25.9 / −28.3% vs −2.2% (4 / 9 / 12 mg)[5]; Lilly 2026-05-21
TRIUMPH-2Obesity with type 2 diabetes1,15280TR: −11.9 / −16.8 / −18.8% vs −5.1%. Eff: −12.7 / −19.1 / −20.8% vs −4.0%[17]; Lilly releases
TRIUMPH-3BMI 35+ with heart disease1,94980Eff: −21.6% (9 mg), −22.6% (12 mg) vs −3.2%Lilly press release 2026-07-23[12]
TRIUMPH-4Obesity with knee osteoarthritis44568TR: −20.0 / −23.7% vs −4.6%. Eff: −26.4 / −28.7% vs −2.1% (9 / 12 mg)[15]; Lilly 2025-12-11
TRANSCEND-T2D-1Type 2 diabetes, diet and exercise only53740TR: −11.5 / −13.9 / −15.3% vs −2.6%; HbA1c −1.69 to −1.94 vs −0.81[11]
TRANSCEND-T2D-2Type 2 diabetes, open-label vs Ozempic 2 mg1,29880Eff: −19.5% (9 mg), −20.9% (12 mg) vs −9.4% (Ozempic)Lilly press release 2026-10-28[14]

One row per trial. TR = treatment-regimen estimand; Eff = efficacy estimand. Results from different trials differ in population, length and estimand, so they are not a head-to-head comparison.

Do you need to stay on it? TRIUMPH-6 is testing what happens to weight when people stay on retatrutide or switch to placebo after 80 weeks[18]. It has no results yet; primary completion is estimated for 2028-04.

  • Liver fat: in 98 people with fatty liver from the phase 2 trial, liver fat fell to the normal range by week 48 in 27% (1 mg), 52% (4 mg), 79% (8 mg) and 86% (12 mg) vs 0% on placebo[19].
  • Sleep apnoea: in the TRIUMPH-1 sleep apnoea group, breathing events per hour fell by 22.9, 34.3 and 31.7 (4 / 9 / 12 mg) vs 9.9 on placebo[20].
  • Knee pain: in TRIUMPH-4, WOMAC pain scores fell by 3.96 (9 mg) and 3.74 (12 mg) vs 2.12 on placebo[15].
  • Heart events: TRIUMPH-3 counted 44 major heart events on retatrutide vs 52 on placebo, hazard ratio 0.82 (95% CI 0.55 to 1.22). The trial was not designed to test this, so there is no conclusion on heart events (Lilly press release, 2026-07-23). A dedicated outcomes trial of about 10,000 people is running[21].

Retatrutide dosing studied in trials

Every trial arm and the phase 3 step-up scheme. Not a dosing guide.
There is no approved retatrutide dose
Each row below is a published trial arm: what was tested, in whom, and what happened. It is not a dosing guide or a recommendation.
Published trial arms
Trial and sourceDose tested and how it was reachedWeeksWeight change
Phase 1b T2DSmall human study[3]0.5, 1.5, 3 mg; 3→6 mg; 3→6→9→12 mgFixed or stepped as named12Up to −8.96 kg vs placebo (3→6→9→12 mg)
Phase 2 obesityHuman randomised trial[4]1 mgFixed48−8.7%
Phase 2 obesityHuman randomised trial[4]4 mgTwo arms: start 2 mg, or start 4 mg48−17.1% (both 4 mg arms)
Phase 2 obesityHuman randomised trial[4]8 mgTwo arms: start 2 mg, or start 4 mg48−22.8% (both 8 mg arms)
Phase 2 obesityHuman randomised trial[4]12 mgStart 2 mg48−24.2%
Phase 2 obesityHuman randomised trial[4]Placebo–48−2.1%
Phase 2 T2DHuman randomised trial[16]0.5 mgFixed36−3.19%
Phase 2 T2DHuman randomised trial[16]4 mgStart 2 mg36−7.92%
Phase 2 T2DHuman randomised trial[16]4 mgNo escalation36−10.37%
Phase 2 T2DHuman randomised trial[16]8 mg (slow)Start 2 mg36−16.81%
Phase 2 T2DHuman randomised trial[16]8 mg (fast)Start 4 mg36−16.34%
Phase 2 T2DHuman randomised trial[16]12 mgStart 2 mg36−16.94%
Phase 2 T2DHuman randomised trial[16]Placebo / dulaglutide 1.5 mgComparators36−3.00% / −2.02%
TRIUMPH-1Human randomised trial[5]4 mg2 → 4 mg, step every 4 weeks80−17.6% TR / −19.0% Eff
TRIUMPH-1Human randomised trial[5]9 mg2 → 4 → 6 → 9 mg80−23.7% TR / −25.9% Eff
TRIUMPH-1Human randomised trial[5]12 mg2 → 4 → 6 → 9 → 12 mg80−25.0% TR / −28.3% Eff
TRIUMPH-1Human randomised trial[5]Placebo–80−3.9% TR / −2.2% Eff
TRIUMPH-1 extensionCompany press releaseLilly 2026-05-21 ·[6]4 mg → MTD; 9 mg → MTD; 12 mg → MTDBMI 35+, n=532104−27.9 / −29.5 / −30.3% Eff
TRIUMPH-1 extensionCompany press releaseLilly 2026-05-21 ·[6]Placebo → retatrutideBMI 35+104−19.2% Eff
TRIUMPH-2Human randomised trial[17]4 / 9 / 12 mgSame scheme as TRIUMPH-180−11.9 / −16.8 / −18.8% TR
TRIUMPH-2Human randomised trial[17]Placebo–80−5.1% TR
TRIUMPH-3Company press releaseLilly 2026-07-23 ·[12]9 / 12 mgStart 2 mg, step every 4 weeks80−21.6 / −22.6% Eff
TRIUMPH-3Company press releaseLilly 2026-07-23 ·[12]Placebo–80−3.2% Eff
TRIUMPH-4Human randomised trial[15]9 mg2 → 4 → 6 → 9 mg68−20.0% TR / −26.4% Eff
TRIUMPH-4Human randomised trial[15]12 mg2 → 4 → 6 → 9 → 12 mg68−23.7% TR / −28.7% Eff
TRIUMPH-4Human randomised trial[15]Placebo–68−4.6% TR / −2.1% Eff
TRANSCEND-T2D-1Human randomised trial[11]4 / 9 / 12 mgNot stated in the abstract40−11.5 / −13.9 / −15.3% vs −2.6% placebo
TRANSCEND-T2D-2Company press releaseLilly 2026-10-28 ·[14]9 / 12 mg vs Ozempic 2 mgStart 2 mg, step every 4 weeks80−19.5 / −20.9% vs −9.4% Eff

All arms were once weekly, under the skin. TR = treatment-regimen estimand; Eff = efficacy estimand. Phase 2 figures are least-squares means. The 104-week rows are an extension of TRIUMPH-1 in people with a BMI of 35 or more; "MTD" is the term Lilly used for the dose people moved to.

How the phase 3 trials stepped up. Lilly's releases for TRIUMPH-1 (2026-05-21) and TRIUMPH-4 (2025-12-11) say every arm started at 2 mg and increased every four weeks; the TRIUMPH-2 and TRIUMPH-3 releases give the same start and interval. The table shows that trial scheme. It is a description of the trials, not a schedule to follow.

Trial weeksWeekly dose givenArms that stopped here
1 to 42 mg
5 to 84 mg4 mg arm
9 to 126 mg
13 to 169 mg9 mg arm
17 onward12 mg12 mg arm

Source: Lilly press releases for TRIUMPH-1 (2026-05-21) and TRIUMPH-4 (2025-12-11). Each step lasted 4 weeks.

  • No trial started at 0.25 mg, and no trial used a "1 mg start, then 0.5 mg steps" scheme. Phase 3 trials started at 2 mg (Lilly releases above).
  • Phase 3 steps were 2, 4, 6, 9 and 12 mg. Charts with an 8 mg step mix the phase 2 8 mg arm into the phase 3 scheme.
  • 10 mg, 20 mg and 30 mg are vial label sizes seen in searches, not trial doses. The highest weekly dose in any published trial was 12 mg (table above).

How many mg per week did trial participants take? In phase 3, the weekly maintenance arms were 4, 9 and 12 mg, reached by the steps above. Phase 2 also tested 0.5, 1 and 8 mg arms. These are facts about the trials and not an amount anyone should take.

Retatrutide calculator: vial and syringe arithmetic

This tool converts the numbers on a vial label into concentration and U-100 syringe units. A worked example with no dose in it: 10 mg dissolved in 2 mL of water gives 5 mg per mL. The amount of water you add does not change how much drug is in the vial; it only changes how much each unit contains. That is the whole answer to "how much bac water for a 30 mg vial": the volume is a choice, and the calculator shows what each choice means.

Retatrutide is not approved, and no legal product or label exists
This calculator does arithmetic only (mg, mL and syringe units). It does not suggest a dose, and the trial arms above are not instructions. Products sold online as retatrutide are not the trial drug, and their contents cannot be checked.

Before you use the calculator

  • It does arithmetic on the numbers you type from your own label. It does not suggest an amount or say whether anything is safe for you.
  • It is not medical advice. Check every result with your pharmacist or prescriber before you use it.
  • Its units are for U-100 insulin syringes only (the box or barrel says U-100).
  • In an emergency call 911. For a possible overdose call Poison Help at 1-800-222-1222.

Your answer is saved only in this browser so you are not asked again. See the privacy policy.

The 10, 20 and 30 mg presets are vial label sizes people search for. They are not doses, and no trial gave these amounts. Mixing steps: how to reconstitute peptides and bacteriostatic water. Full tool: reconstitution calculator.

Retatrutide side effects reported in trials

Side-effect tables for each trial, dysesthesia, and who stopped.

In TRIUMPH-1, on the top dose (12 mg) about 4 in 10 people had nausea, vs about 1 in 7 on placebo (42.4% vs 14.8%). About 1 in 3 had diarrhoea (32.0% vs 13.5%). About 1 in 4 vomited (25.3% vs 4.8%). About 1 in 9 stopped because of side effects, vs 1 in 20 on placebo (11.3% vs 4.9%). Source: Lilly release, 2026-05-21[6]. What helps is in living with it day to day; warning signs are in when to call a doctor.

Stomach and gut effects were the most common side effects in every trial. In phase 2 they were dose-related, mostly mild to moderate, and partly reduced by starting at 2 mg instead of 4 mg[4]. Each trial reported its own figures, so each trial gets its own table below.

TRIUMPH-1: side effects on 12 mg vs placebo (% of people) Retatrutide 12 mg Placebo

Scale: 0–42.4%

Nausea42.4% vs 14.8%
Diarrhoea32% vs 13.5%
Constipation26.1% vs 10.9%
Vomiting25.3% vs 4.8%
Dysesthesia (skin sensitivity)12.5% vs 0.9%
Urinary tract infection8.4% vs 5.3%

Source: Lilly press release on TRIUMPH-1, 2026-05-21 (company press release; trial record[6]). All three doses are in the table below.

Event4 mg9 mg12 mgPlacebo
Nausea28.638.442.414.8
Diarrhoea25.234.132.013.5
Constipation23.825.926.110.9
Vomiting10.622.825.34.8
Dysesthesia5.112.312.50.9
Urinary tract infection7.58.88.45.3

TRIUMPH-1, 80 weeks, % of people. Source: Lilly press release, 2026-05-21; trial record[6].

Event4 mg9 mg12 mgPlacebo
Diarrhoea27343413
Nausea1421288
Low blood pressure156<1
Dysesthesia4671

TRIUMPH-2 (obesity with type 2 diabetes), 80 weeks, % of people. Source: Lancet 2026[17].

Event9 mg12 mgPlacebo
Diarrhoea30.124.48.7
Nausea21.722.45.8
Dysesthesia6.46.41.3

TRIUMPH-3 (heart disease), 80 weeks, % of people. Source: Lilly press release, 2026-07-23; trial record[12]. Not yet peer-reviewed.

Event9 mg12 mgPlacebo
Nausea38.143.210.7
Diarrhoea34.733.113.4
Vomiting20.420.90.0
Constipation21.825.08.7
Dysesthesia8.820.90.7

TRIUMPH-4 (knee osteoarthritis), 68 weeks, % of people. Source: Lilly press release, 2025-12-11; trial record[9].

Skin sensitivity (dysesthesia). Dysesthesia is the trial term for unusual skin sensations such as burning, tingling or sensitivity to touch. It is reported more often with retatrutide than with placebo in every phase 3 trial above: from 4% (TRIUMPH-2, 4 mg) to 20.9% (TRIUMPH-4, 12 mg), against 0.7% to 1.3% on placebo. The sources above report how often it happened. None of them explains why it happens, and we do not guess.

Dysesthesia on 12 mg vs placebo, by trial (% of people) Retatrutide 12 mg Placebo

Scale: 0–20.9%

TRIUMPH-112.5% vs 0.9%
TRIUMPH-27% vs 1%
TRIUMPH-36.4% vs 1.3%
TRIUMPH-420.9% vs 0.7%

Each bar comes from a different trial with different people and lengths, so the bars are not a comparison between trials. Sources: Lilly releases for TRIUMPH-1 (2026-05-21), TRIUMPH-3 (2026-07-23) and TRIUMPH-4 (2025-12-11); Lancet[17] for TRIUMPH-2.

Heart rate and blood pressure. In phase 2, heart rate rose with dose, peaked at week 24 and then declined[4]. In TRIUMPH-2, low blood pressure was reported in 1%, 5% and 6% (4 / 9 / 12 mg) vs under 1% on placebo[17].

TrialRetatrutide armsPlaceboSource
TRIUMPH-14.1% / 6.9% / 11.3% (4 / 9 / 12 mg)4.9%Lilly 2026-05-21[6]
TRIUMPH-24% / 12% / 8% (4 / 9 / 12 mg)5%[17]
TRIUMPH-39.8% / 13.5% (9 / 12 mg)4.8%Lilly 2026-07-23[12]
TRIUMPH-412.2% / 18.2% (9 / 12 mg)4.0%Lilly 2025-12-11[9]
TRANSCEND-T2D-12% to 5%0%[11]
TRANSCEND-T2D-24.8% / 7.9% (9 / 12 mg)2.7% (Ozempic, no placebo arm)Lilly 2026-10-28[14]

People who stopped treatment because of side effects. In TRIUMPH-4, Lilly says rates tracked starting BMI and included people who stopped because of what they saw as too much weight loss. TRIUMPH-2 counts stopping for side effects or death.

Low blood sugar. No severe hypoglycaemia was reported in the phase 2 diabetes trial[16] or in TRANSCEND-T2D-1[11].

  • Serious adverse events were more common with retatrutide than placebo in TRIUMPH-4; the abstract does not give the numbers[15].
  • Pancreatitis, gallbladder problems, heart rhythm problems and eye (retinopathy) events: we did not find rates for these in the papers and releases we read.
  • Beyond 104 weeks: no safety data have been published.

Muscle and body composition

The only body-composition data: a 103-person scan substudy.

The only published body-composition data come from a DXA scan substudy of the phase 2 type 2 diabetes trial, with 103 people who finished it. At 36 weeks, total fat mass fell 23.2% on 12 mg vs 4.5% on placebo. The authors say the share of weight lost as lean mass was similar to other obesity treatments[22].

No trial has compared lean-mass loss on retatrutide with tirzepatide, so there is no evidence that it protects muscle better. No trial has tested whether it helps build muscle. For the cross-trial picture, see retatrutide vs tirzepatide.

Products sold online as retatrutide

FDA warning letters, lawsuits, and why online products are not the trial drug.

The FDA says retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition. Its warning letters have gone to telehealth firms marketing retatrutide, ingredient distributors selling it to compounders, outsourcing facilities repackaging it, and sellers labelling it "for research purposes" or "not for human consumption"[13]. Two examples: GenoGenix LLC repackaged semaglutide, tirzepatide and retatrutide (FDA warning letter 718739, 2026-01-20), and Gram Peptides sold "Retatrutide" labelled "Research Use Only" (FDA warning letter 721806, 2026-03-31).

BioPharma Dive reported on 2026-08-12 that Lilly had filed six lawsuits, against a compounding pharmacy, a wellness business and four "research use only" sellers. A JAMA news feature covers online retatrutide sales[23]. Because these products are not the trial drug, trial results and side-effect rates do not describe them.

What people who bought it report. A study of Reddit posts from 7,823 people who said they used non-approved retatrutide could not verify what they took or how much. The most-reported effect was increased appetite (17.1%). These are self-reports, not side-effect rates[24].

The only legal routes are a clinical trial or the expanded access programme described in status and timeline.

Ongoing retatrutide trials

Nine trials still running, with registry dates.
TrialRegistryPhaseWhat it testsPeoplePrimary completion
TRIUMPH-5[7]3Retatrutide vs tirzepatide, obesity; weight at week 80~8002026-11
TRIUMPH-6[18]3Keeping weight off: 80-week lead-in, then dose 1, dose 2 or placebo for 36 weeks6432028-04
TRIUMPH-7[25]3Chronic low back pain5862027-09
TRIUMPH-8[26]3bPlacebo-controlled, 56 weeks2502027-06
TRIUMPH-9[27]3bThree dose-escalation schemes, week 1046002028-10
TRANSCEND-T2D-3[28]3Type 2 diabetes with moderate or severe kidney impairment, on basal insulin3412026-10-26
Heart and kidney outcomes[21]3Major heart and kidney events, about 5 years~10,0002029-02
MASLD master protocol[29]3Fatty liver disease, several drugs~4,5002030-08
GZBF[30]2New dose-escalation study, 1 to 12 mg arms–2027-03

Read from ClinicalTrials.gov on 2026-11-17. Completion dates are the registry's estimates for primary completion.

TRIUMPH-5 is the only head-to-head trial against tirzepatide. This page and the comparison article will be updated when it reports.

Retatrutide compared with other drugs

Tirzepatide (Mounjaro, Zepbound). No trial has compared them head to head and reported yet. TRIUMPH-5 is doing that now[7]; each drug's own results are side by side in retatrutide vs tirzepatide.

Semaglutide (Ozempic). The only head-to-head result so far is TRANSCEND-T2D-2 in type 2 diabetes: −20.9% weight on retatrutide 12 mg vs −9.4% on Ozempic 2 mg at 80 weeks (efficacy estimand, open-label, Lilly press release 2026-10-28, not yet peer-reviewed)[14].

No published trial has combined retatrutide with MOTS-c, cagrilintide, BPC-157 or tirzepatide.

Retatrutide vs tirzepatide →Two receptors vs three. No head-to-head result yet; TRIUMPH-5 is running.
Eloralintide vs retatrutide →Two Lilly drugs: an amylin agonist and a triple agonist. No trial compares them.
Eloralintide →Lilly's weekly amylin drug in phase 3.

Sources

  1. 1.FDA MedWatch
  2. 2.serious side effects in the Zepbound Medication Guide, a related approved drug
  3. 3.Urva et al. Phase 1b in type 2 diabetes. Lancet 2022. PMID 36354040 Small human study
  4. 4.Jastreboff et al. Phase 2 obesity trial. NEJM 2023. PMID 37366315 Human randomised trial
  5. 5.Jastreboff et al. TRIUMPH-1. NEJM 2026. PMID 42814954 Human randomised trial
  6. 6.TRIUMPH-1, NCT05929066 Trial registry
  7. 7.TRIUMPH-5 (vs tirzepatide), NCT06662383 Trial registry
  8. 8.Coskun et al. LY3437943, a novel triple agonist. Cell Metab 2022. PMID 35985340 Cell
  9. 9.TRIUMPH-4, NCT05931367 Trial registry
  10. 10.Expanded access programme, NCT07629401 Trial registry
  11. 11.Bajaj et al. TRANSCEND-T2D-1. Lancet 2026. PMID 42250575 Human randomised trial
  12. 12.TRIUMPH-3, NCT05882045 Trial registry
  13. 13.FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current 2026-10-01) Regulator
  14. 14.TRANSCEND-T2D-2, NCT06260722 Trial registry
  15. 15.Schnitzer et al. TRIUMPH-4 and TRIUMPH-1 knee osteoarthritis. NEJM 2026. PMID 43001755 Human randomised trial
  16. 16.Rosenstock et al. Phase 2 type 2 diabetes trial. Lancet 2023. PMID 37385280 Human randomised trial
  17. 17.Bellido et al. TRIUMPH-2. Lancet 2026. PMID 42810372 Human randomised trial
  18. 18.NCT06859268
  19. 19.Sanyal et al. Liver-fat substudy. Nat Med 2024. PMID 38858523 Human randomised trial
  20. 20.Sleep apnoea results, TRIUMPH-1 and TRIUMPH-2. NEJM 2026. PMID 42904878 Human randomised trial
  21. 21.NCT06383390
  22. 22.Body-composition (DXA) substudy. Lancet Diabetes Endocrinol 2025. PMID 40609566 Human randomised trial
  23. 23.JAMA 2026, PMID 42853576
  24. 24.Sehgal et al. Self-reported retatrutide use on Reddit (cross-sectional). JAMA Netw Open 2026. PMID 42873503 Small human study
  25. 25.NCT07035093
  26. 26.NCT07232719
  27. 27.NCT07357415
  28. 28.NCT06297603
  29. 29.NCT07165028
  30. 30.NCT07467447
  31. 31.TRIUMPH-2, NCT05929079 Trial registry
  32. 32.TRANSCEND-T2D-1, NCT06354660 Trial registry
On this pageWhat the trials saw, week by weekLiving with it day to dayWhen to call a doctorIs it working? How to track itWhy results varySwitching from tirzepatide to retatrutideWhat is retatrutide?How retatrutide worksIs retatrutide approved? Status and timelineWhat the retatrutide trials foundRetatrutide dosing studied in trialsRetatrutide calculator: vial and syringe arithmeticRetatrutide side effects reported in trialsMuscle and body compositionProducts sold online as retatrutideOngoing retatrutide trialsRetatrutide compared with other drugsSources